Argent Trust Co buys $5,308,998 stake in Pfizer (PFE)

Pfizer (PFE) : Argent Trust Co scooped up 2,676 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 158,100 shares of Pfizer which is valued at $5,308,998.Pfizer makes up approximately 1.70% of Argent Trust Co’s portfolio.

Pfizer opened for trading at $33.38 and hit $33.59 on the upside on Friday, eventually ending the session at $33.58, with a gain of 0.03% or 0.01 points. The heightened volatility saw the trading volume jump to 2,31,70,974 shares. Company has a market cap of $207,663 M.

Other Hedge Funds, Including , Calvert Investment Management boosted its stake in PFE in the latest quarter, The investment management firm added 6,182 additional shares and now holds a total of 1,061,538 shares of Pfizer which is valued at $35,646,446. Pfizer makes up approx 1.58% of Calvert Investment Management’s portfolio.Advisors Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 11,389 additional shares and now holds a total of 21,656 shares of Pfizer which is valued at $708,368. Pfizer makes up approx 0.07% of Advisors Capital Management’s portfolio.Chemung Canal Trust Co boosted its stake in PFE in the latest quarter, The investment management firm added 60,022 additional shares and now holds a total of 286,242 shares of Pfizer which is valued at $9,523,271. Pfizer makes up approx 2.16% of Chemung Canal Trust Co’s portfolio.Schaper Benz Wise Investment Counsel Incwi boosted its stake in PFE in the latest quarter, The investment management firm added 2,450 additional shares and now holds a total of 215,618 shares of Pfizer which is valued at $7,173,611. Pfizer makes up approx 1.32% of Schaper Benz Wise Investment Counsel Incwi’s portfolio.Davis R M Inc boosted its stake in PFE in the latest quarter, The investment management firm added 5,425 additional shares and now holds a total of 65,417 shares of Pfizer which is valued at $2,176,424. Pfizer makes up approx 0.11% of Davis R M Inc’s portfolio.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Many Wall Street Analysts have commented on Pfizer. Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.